Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

It is a multi-center, open-label study designed to evaluate the safety and potential efficacy of the combination of pepinemab and avelumab in subjects with advanced NSCLC.